ZUMA-1 update: durable survival in R/R DLBCL patients treated with axi-cel
Sattva Neelapu • 4 Jan 2019
ECHELON-1 AYA subgroup results: brentuximab vedotin plus AVD vs. ABVD
Graham Collins • 16 Jan 2019
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.